<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499954</url>
  </required_header>
  <id_info>
    <org_study_id>CM9 diabetes_sensor</org_study_id>
    <nct_id>NCT00499954</nct_id>
  </id_info>
  <brief_title>Investigation of Correlation Between Concentrations of Glucose in Blood and Interstitial Fluid in Type 1 Diabetics</brief_title>
  <official_title>An Open, Mono-Centre Trial to Investigate the Correlation Between Concentrations of Glucose in Arterialized Venous Blood and Subcutaneous Interstitial Fluid Applying Different Extracorporeal Sensor Techniques in Type 1 Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a mono-centre trial performed at the Center for Clinical Research at the Medical&#xD;
      University Graz. There will be a screening information and a study visit.In the study visit&#xD;
      arterialized venous blood glucose values will be monitored and subcutaneous sampling of&#xD;
      interstitial fluid (ISF) with microdialysis for glucose determination will be performed.&#xD;
      Additionally to the laboratory analysis of the subcutaneous glucose samples, the glucose will&#xD;
      be measured with extracorporeal on-line sensors and two marketed devices (Guardian RT and&#xD;
      Glucoday S).The study visit will last 30 hours starting with the insertion of microdialysis&#xD;
      catheters in the abdominal subcutaneous tissue and the insertion of the catheters for the&#xD;
      Glucoday S system and Guardian RT system. The primary hypothesis of the study is:&#xD;
      Interstitial fluid glucose concentration profiles correlate to the arterialized venous blood&#xD;
      glucose concentration profile in type 1 diabetic subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microdialysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Guardian RT</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glucoday S</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent obtained before any trial-related activities.&#xD;
&#xD;
          -  Skin fold thickness of minimally 5 mm&#xD;
&#xD;
          -  Age of patients in the range from 19 to 60 years.&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe acute and/or chronic diseases&#xD;
&#xD;
          -  Mental incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or co-operation.&#xD;
&#xD;
          -  Taking of any vasoactive substances or anticoagulation medication.&#xD;
&#xD;
          -  Diseases of the skin which could interfere with application of the catheters&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Pieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Graz, Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Graz - Clinical Research Center</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <last_update_submitted>July 11, 2007</last_update_submitted>
  <last_update_submitted_qc>July 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2007</last_update_posted>
  <keyword>microdialysis</keyword>
  <keyword>subcutaneous adipose tissue</keyword>
  <keyword>glucose sensor</keyword>
  <keyword>glucose monitoring</keyword>
  <keyword>type 1 diabetes</keyword>
  <keyword>Guardian RT</keyword>
  <keyword>Glucoday S</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

